173 related articles for article (PubMed ID: 24991188)
41. Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans.
Kim MH; Seong MC; Kwak NH; Yoo JS; Huh W; Kim TG; Han H
Am J Ophthalmol; 2000 Feb; 129(2):173-7. PubMed ID: 10682969
[TBL] [Abstract][Full Text] [Related]
42. Humoral immune response directed against LEDGF in patients with VKH.
Yamada K; Senju S; Shinohara T; Nakatsura T; Murata Y; Ishihara M; Nakamura S; Ohno S; Negi A; Nishimura Y
Immunol Lett; 2001 Oct; 78(3):161-8. PubMed ID: 11578690
[TBL] [Abstract][Full Text] [Related]
43. Increased IL-7 expression in Vogt-Koyanagi-Harada disease.
Yang Y; Xiao X; Li F; Du L; Kijlstra A; Yang P
Invest Ophthalmol Vis Sci; 2012 Feb; 53(2):1012-7. PubMed ID: 22247488
[TBL] [Abstract][Full Text] [Related]
44. Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent Vogt-Koyanagi-Harada disease.
Li F; Yang P; Liu X; Wang C; Hou S; Kijlstra A
Arch Ophthalmol; 2010 Nov; 128(11):1449-54. PubMed ID: 21060047
[TBL] [Abstract][Full Text] [Related]
45. Expression and role of interleukin-9 in Vogt-Koyanagi-Harada disease.
Peng Z; Jiang S; Wu M; Zhou X; Wang Q
Mol Vis; 2017; 23():538-547. PubMed ID: 28761327
[TBL] [Abstract][Full Text] [Related]
46. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
Steitz J; Brück J; Lenz J; Büchs S; Tüting T
J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
[TBL] [Abstract][Full Text] [Related]
47. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.
Norose K; Yano A
Br J Ophthalmol; 1996 Nov; 80(11):1002-8. PubMed ID: 8976730
[TBL] [Abstract][Full Text] [Related]
48.
Anukul N; Pathanapitoon K; Leetrakool N; Guntiya T; Wita R; Palacajornsuk P; Klangsinsirikul P
Ocul Immunol Inflamm; 2021 Feb; 29(2):260-263. PubMed ID: 32965138
[TBL] [Abstract][Full Text] [Related]
49. New insights into Vogt-Koyanagi-Harada disease.
Damico FM; Bezerra FT; Silva GC; Gasparin F; Yamamoto JH
Arq Bras Oftalmol; 2009; 72(3):413-20. PubMed ID: 19668980
[TBL] [Abstract][Full Text] [Related]
50. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
51. Vogt-Koyanagi-Harada syndrome in patients of Vietnamese ancestry.
Riddington L; Hall AJ; Tait B; Nicholson I; Varney M
Aust N Z J Ophthalmol; 1996 May; 24(2):147-9. PubMed ID: 9199747
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
[TBL] [Abstract][Full Text] [Related]
53. Immunologic analysis of cerebrospinal fluid lymphocytes in Vogt-Koyanagi-Harada disease.
Norose K; Yano A; Aosai F; Segawa K
Invest Ophthalmol Vis Sci; 1990 Jul; 31(7):1210-6. PubMed ID: 2142146
[TBL] [Abstract][Full Text] [Related]
54. Leptin increases in Vogt-Koyanagi-Harada (VKH) disease and promotes cell proliferation and inflammatory cytokine secretion.
Liu L; Yang P; He H; Lin X; Jiang L; Chi W; Zhao C; Zhou H
Br J Ophthalmol; 2008 Apr; 92(4):557-61. PubMed ID: 18245271
[TBL] [Abstract][Full Text] [Related]
55. Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease.
Wang C; Tian Y; Lei B; Xiao X; Ye Z; Li F; Kijlstra A; Yang P
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4668-75. PubMed ID: 22669715
[TBL] [Abstract][Full Text] [Related]
56. Expression of Fas antigen on helper T lymphocytes in Vogt-Koyanagi-Harada disease.
Ohta K; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 1998 Jun; 236(6):434-9. PubMed ID: 9646088
[TBL] [Abstract][Full Text] [Related]
57. A study of KIR genes and HLA-C in Vogt-Koyanagi-Harada disease in Saudi Arabia.
Sheereen A; Gaafar A; Iqneibi A; Eldali A; Tabbara KF; Adra C; Al-Hussein K
Mol Vis; 2011; 17():3523-8. PubMed ID: 22219647
[TBL] [Abstract][Full Text] [Related]
58. Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders.
Egbeto IA; Garelli CJ; Piedra-Mora C; Wong NB; David CN; Robinson NA; Richmond JM
Front Immunol; 2020; 11():590558. PubMed ID: 33384688
[TBL] [Abstract][Full Text] [Related]
59. Pathogenesis of Vogt-Koyanagi-Harada disease.
Yamaki K; Gocho K; Sakuragi S
Int Ophthalmol Clin; 2002; 42(1):13-23. PubMed ID: 12189608
[No Abstract] [Full Text] [Related]
60. TET2-mediated upregulation of 5-hydroxymethylcytosine in LRRC39 promoter promotes Th1 response in association with downregulated Treg response in Vogt-Koyanagi-Harada disease.
Zhang W; Chen Z; Yi K; Su G; Liu Y; Deng Y; Zhang Y; Cao Q; Pu Y; Luo X; Lai Y; Yang P
Clin Immunol; 2023 May; 250():109323. PubMed ID: 37019422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
